The origin of DCprime lies in a finding originally made by the Department of Medical Oncology at the VUmc in Amsterdam (now Amsterdam UMC). Here it was discovered that tumour cell lines could be differentiated into dendritic cells, providing the basis for the DCOne® platform. Nowadays, DCOne® vaccines are manufactured as off-the-shelf products. Based on their origin as an AML cell line, DCOne® cells express various tumour antigens, making them useful vaccines for haemato-oncology diseases including AML and multiple myeloma. The cells provide a potent stimulus to the recipients’ immune system and can be loaded with additional antigens to prepare tumour-specific vaccine formulations against other types of cancer, including solid tumours.
Cell based cancer vaccines
DCprime has both the infrastructure and capabilities to bring cancer immunotherapeutics to clinic. Initially exploiting the proprietary DCOne® platform, DCprime is developing cell based vaccines against different types of cancer.
Immuno-oncology beyond T cells
Since successful vaccination requires an immune system capable of mounting an effective response to the vaccine, DCprime continues to invest in research into furthering understanding of the condition of the immune system during or after treatment of cancer.